Home › Triple-Negative Breast Cancer › California › San Francisco
Triple-Negative Breast Cancer clinical trials in San Francisco, CA
11 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RecruitingPhase 3
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016), San Francisco
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
- Kaiser Permanente - San Francisco ( Site 0080), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
RecruitingPhase 1/2
- University of California, San Francisco, San Francisco
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- City of Hope (Duarte), San Francisco
- UCSF Medical Center, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecruitingPhase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
RecruitingPhase 2
- University of California, San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingPhase 2
- University of California San Francisco (UCSF), San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RecruitingPhase 2
- University of California San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
RecruitingObservational studyHealthy volunteers welcome
- University of California, San Francisco, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
RecruitingObservational study
- Curebase, San Francisco
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer28 studies
- Lung Cancer22 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Ovarian Cancer19 studies
- Colorectal Cancer18 studies
- Cardiovascular Disease18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.